Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Capital Expenditures (2016 - 2025)

Haemonetics (HAE) has 17 years of Capital Expenditures data on record, last reported at $6.3 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 25.71% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $30.8 million, up 1.46%, while the annual FY2025 figure was $39.3 million, 3.02% up from the prior year.
  • Capital Expenditures reached $6.3 million in Q4 2025 per HAE's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $93.1 million in Q2 2023 and bottomed at $3.8 million in Q2 2025.
  • Average Capital Expenditures over 5 years is $19.6 million, with a median of $12.8 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: skyrocketed 226.65% in 2022, then crashed 92.82% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $20.8 million in 2021, then fell by 19.05% to $16.8 million in 2022, then dropped by 13.07% to $14.6 million in 2023, then tumbled by 41.65% to $8.5 million in 2024, then dropped by 25.71% to $6.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $6.3 million in Q4 2025, $5.0 million in Q3 2025, and $3.8 million in Q2 2025.